Results 281 to 290 of about 457,916 (395)

Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study [PDF]

open access: green, 2006
Roger K. Schindhelm   +6 more
openalex   +1 more source

Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad
Jia Sun   +19 more
wiley   +1 more source

Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan [PDF]

open access: bronze, 2006
Chien‐Hua Chen   +6 more
openalex   +1 more source

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao   +5 more
wiley   +1 more source

Alanine–glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer [PDF]

open access: green, 2006
Eduardo Salido   +8 more
openalex   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy